U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141095) titled 'A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection' on July 30.
Brief Summary: The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings.
The participants will be treated with maribavir for up to 8 weeks.
Study Start Date: Sept. 25
Study Type: OBSERVATIONAL
Condition:
Infections, Cytomegalovirus
Intervention:
DRUG: maribavir
Maribavir tablets are administered orally at a dose of 0.4 g per administration (2 tablets of ...